Compare ICUI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | TNGX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 1995 | 2020 |
| Metric | ICUI | TNGX |
|---|---|---|
| Price | $165.97 | $22.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $193.38 | $47.09 |
| AVG Volume (30 Days) | 193.4K | ★ 4.1M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.62 | 26.89 |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $2,231,262,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.44 | N/A |
| P/E Ratio | $85.24 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $113.37 | $7.37 |
| 52 Week High | $192.85 | $34.39 |
| Indicator | ICUI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 44.55 |
| Support Level | $164.09 | $20.46 |
| Resistance Level | $167.67 | $25.68 |
| Average True Range (ATR) | 4.51 | 1.77 |
| MACD | 0.85 | 0.13 |
| Stochastic Oscillator | 86.13 | 18.07 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.